The FDA has expanded the approval of Sanofi's Tzield (teplizumab) to children as young as 1 year old with stage 2 type 1 diabetes (T1D), a significant step forward from its previous approval for patients aged 8 and older. Tzield works as a CD3-directed monoclonal antibody that modulates the immune system to delay the progression from stage 2 to stage 3 type 1 diabetes (insulin-dependence), making it the first disease-modifying therapy for T1D. This expansion is a major milestone, particularly for families of very young children who now have access to a treatment that can meaningfully change the course of the disease.

The approval was supported by the PETITE-T1D phase 4 study, which evaluated the safety and pharmacokinetics of Tzield in young children. The study included 23 participants under the age of 8 who received a 14-day intravenous infusion course, providing the clinical data needed to support this younger age group. The findings gave regulators the confidence to extend access to one of the most vulnerable patient populations affected by type 1 diabetes.

Beyond the U.S., Tzield has already gained broad international recognition, with approvals in the EU under the name Teizeild, as well as in the UK, China, Canada, Israel, Saudi Arabia, the UAE, Kuwait, and Brazil for adults and pediatric patients aged 8 and older with stage 2 type 1 diabetes. The FDA is also currently reviewing Tzield for an additional indication to delay the progression of stage 3 type 1 diabetes in newly diagnosed patients aged 8 and older.

Researchers are also exploring other approaches for type 1 diabetes, including immunotherapies and cell-based therapies, though these remain investigational. We have covered many of these potential preventions, delays and cures on our podcast, including a conversation with Breakthrough T1D's CEO Dr. Aaron J. Kowalski about the organization's mission to cure type 1 diabetes and the cell therapy research it is accelerating. For more, visit our Research page.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.